We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 24% below its sector, cheaper than its peers on earnings.
Tibet Weixinkang Medicine Co., Ltd., a pharmaceutical enterprise headquartered in Lhasa, China, is dedicated to the entire lifecycle of medicinal products within the country, encompassing their research and development, manufacturing, and sales. The company's diverse range of offerings includes specialized vitamins for parenteral nutrition, electrolyte solutions, intravenous iron preparations, antibiotic medications, and therapies designed for digestive system and liver conditions. Among its specific injectable products are multivitamins, potassium magnesium aspartate, iron sucrose, and potassium aspartate. Established in 2006, the firm operated under the name Weixinkang Medicine Youxian Gongsi until its rebranding to Tibet Weixinkang Medicine Co., Ltd. occurred in 2015.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 603676.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
